VolitionRx (NYSEAMERICAN:VNRX) Shares Pass Below 50 Day Moving Average of $1.94

VolitionRx Limited (NYSEAMERICAN:VNRX – Get Rating)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.94 and traded as low as $1.51. VolitionRx shares last traded at $1.54, with a volume of 35,329 shares.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. EF Hutton Acquisition Co. I restated a “buy” rating and set a $6.00 price objective on shares of VolitionRx in a research note on Thursday, March 16th. Benchmark downgraded shares of VolitionRx from a “buy” rating to a “hold” rating in a research note on Wednesday, February 1st. They noted that the move was a valuation call. Finally, StockNews.com assumed coverage on shares of VolitionRx in a research note on Thursday, March 16th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.67.

VolitionRx Stock Performance

The stock has a market cap of $91.61 million, a price-to-earnings ratio of -2.59 and a beta of 1.67. The stock’s 50 day moving average price is $1.94. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.94.

VolitionRx (NYSEAMERICAN:VNRX – Get Rating) last issued its earnings results on Wednesday, March 15th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. VolitionRx had a negative net margin of 9,158.31% and a negative return on equity of 15,493.47%. The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.06 million. Research analysts expect that VolitionRx Limited will post -0.56 EPS for the current year.

Institutional Investors Weigh In On VolitionRx

Hedge funds have recently bought and sold shares of the stock. Creative Planning acquired a new stake in VolitionRx during the fourth quarter worth approximately $32,000. Captrust Financial Advisors lifted its position in VolitionRx by 316.7% during the first quarter. Captrust Financial Advisors now owns 25,000 shares of the medical research company’s stock worth $75,000 after acquiring an additional 19,000 shares during the last quarter. Jane Street Group LLC bought a new position in shares of VolitionRx during the first quarter worth approximately $50,000. Cubist Systematic Strategies LLC bought a new position in shares of VolitionRx during the first quarter worth approximately $58,000. Finally, Virtu Financial LLC bought a new position in shares of VolitionRx during the third quarter worth approximately $51,000. 10.30% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

(Get Rating)

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.